BioSpace News Archive

Business

Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations

Mr. Belkar Brings More Than 20 Years of Global Medical Device Experience, Including at Medtronic and Mazor Robotics

June 3, 2019
·
4 min read
Drug Development

Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting

New Clinical Data Presented Today Included in Recently Submitted NDA to FDA

June 3, 2019
·
8 min read
Drug Development

Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting

Compugen Ltd. announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at the 2019 ASCO Annual Meeting in Chicago, IL.

June 3, 2019
·
4 min read
Pharm Country

CytoSorbents to Present at the Jefferies 2019 Global Healthcare Conference

CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019 in New York, NY.

June 3, 2019
·
4 min read
Pharm Country

Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinson’s at the 5th World Parkinson Congress

Acorda Therapeutics, Inc. announced that it will debut an art gallery inspired by people with Parkinson’s at the 5th World Parkinson Congress in Kyoto, Japan.

June 3, 2019
·
6 min read
Drug Development

Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session

Phase III study protocol for Namodenoson in the treatment of advanced liver cancer patients is now being prepared and will be presented to FDA in an End of Phase II meeting

June 3, 2019
·
7 min read
Drug Development

New Ad-hoc Analysis of Phase 3 HELP Study™ Evaluates Prevention of HAE Attacks with TAKHZYRO® (lanadelumab) During Early Treatment Phase

Data Presented at European Academy of Allergy and Clinical Immunology Congress

June 3, 2019
·
10 min read
Business

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

Astellas Pharma Inc. and Seattle Genetics, Inc. announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44 percent

June 3, 2019
·
11 min read
Biotech Bay

Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce

Non-Browning Romaine lettuce demonstrates improved shelf life, reducing food waste and is not subject to regulation as a product produced through genetic engineering by the USDA

June 3, 2019
·
3 min read
BioCapital

USP Publishes New and Revised Compounding Standards

Standards help ensure quality compounded preparations to safeguard the well-being of patients

June 3, 2019
·
4 min read